



Quality Chemical Industries Limited



Company Profile



Aerial View Of Qcil Factory In Luzira, Kampala.

WHO WE ARE

Quality Chemical Industries Limited (Qcil) is a pharmaceutical company established in 2005 in Kampala, Uganda. The Company is committed to Prioritising **Availability, Accessibility & Affordability** of medicines by manufacturing in Africa.

Publicly Listed on



Uganda
Securities Exchange



Our Purpose

At Qcil, our purpose is clear and bold: to empower Africans not just to heal, but to thrive. **“Life after well”** is more than a slogan, it is a transformative vision that drives everything we do. We believe that true recovery goes beyond treatment. It is about reclaiming vitality, expressing one’s full potential, and living with purpose and pride.

“

WE ARE MORE THAN
MANUFACTURERS OF
QUALITY, AFFORDABLE
MEDICATIONS; WE ARE
ENABLERS OF
“LIFE AFTER WELL”



OUR PRINCIPLES



To become a centre of excellence in the manufacturing of quality, affordable medicines.



To improve the quality of life by increasing access to effective, affordable medicines.



Our Values

PASSIONATE ABOUT QUALITY



Excellence is our standard. From our products to our processes, we are relentless in our pursuit of quality that stands the test of time.

COMMITTED TO AFFORDABILITY



Access to healthcare shouldn't be a privilege. We're dedicated to making high-quality medicines affordable and accessible for all.

PRIORITISING AVAILABILITY



We believe in keeping lifesaving treatments within reach. That's why we ensure our medicines are readily available, whenever they're needed most.

DRIVEN BY INNOVATION



We embrace new ideas and technology to improve the quality of our medicines, processes and impact, delivering life-saving solutions with excellence.

ROOTED IN TRUST



Trust is the foundation of our success. We uphold integrity in every action, building lasting relationships with our communities and each other.

FOUNDATION AND EVOLUTION

> Tracing Qcil's 20-Year Journey

Quality Chemical Industries Limited was incorporated

as a joint venture with Cipla

2005

Cipla acquired controlling shares in the company

and changed its name to Cipla Quality Chemical Industries Limited (CiplaQCIL)

2014

Listed on the Uganda Securities Exchange (USE)

2018

Launch of the upgraded Quality Control Laboratory

2020

Registered name change

from CiplaQcil to Quality Chemical Industries Limited (Qcil)

2024

2010

First WHO prequalified facility in the region for ARVs and ACTs

2016

Company converted to a public company

2019

New warehouse commissioned with 5,000 pallet capacity

2023


Africa Capitalworks (ACW) acquired majority of the company from Cipla.
51.18% of the issued ordinary shares

2025

Construction of second facility and Research & Development (R&D) Center has begun

★ 20 YEARS OF EXCELLENCE

OUR FOOTPRINT



APPROVED
& REGISTERED
IN **31** AFRICAN
MARKETS
/COUNTRIES



25
PRODUCTS
IN OUR PORTFOLIO



OUR COMMITMENT TO EXCELLENCE



QUALITY

We are passionate about excellence and committed to providing the highest standard of products to our customers. Quality is embedded in every step of our operations, including procurement, manufacturing, packaging, testing, distribution, sales and safe product disposal. Our management systems ensure this excellence, guided by our quality policy manual, which cover four key areas:

1. *Process performance and product quality monitoring.*
2. *Corrective and preventive action.*
3. *Change management.*
4. *Management review of process performance and product quality.*

Our focus is on enhancing our quality management systems to meet and exceed the expectations of regulatory authorities such as **WHO, NDA, SAHPRA, ZAZIBONA, EAC and COMESA**. We have digitised our quality management systems using applications like **Trackwise, LIMS & SAP S/4 HANA**.



We recognise that adequate and timely investment in continuing to strengthen these systems will enhance stakeholder confidence and bolster compliance.

PHARMACOVIGILANCE

Pharmacovigilance is an essential component of our quality management, enabling us to adopt adequate measures to identify and raise awareness about the adverse effects of our products. Through a structured customer complaint redressal system, drug safety complaints are directed to our pharmacovigilance team.

The pharmacovigilance team also undertakes measures to review current literature to understand evolving drug reactions. The redressal mechanism is supported by a dedicated phone line and mailbox, where safety-related complaints are received from patients, and healthcare professionals. We have an established Standard Operating Procedures for diligent follow-up with each reporter. As part of this follow-up, we inquire about the patient's safety and obtain adequate information to assess the drug's safety profile.

OUR CAPABILITIES



MANUFACTURING

- Tablets & Hard gelatin capsules
- **1.4 Billion** Tablets Annually
- Granulation - Wet & Dry
- Compression - mono-layer / bi-layer
- Coating



PACKAGING

- Blisters & Bottles



TESTING

- **Quality Control Laboratory**
- APIs, excipients, microbiology
- ICP-MS, LC-HRMS, HPLC, and GC



GC - Gas Chromatography

HPLC - High-Performance Liquid Chromatography

ICP-MS - Inductively Coupled Plasma Mass Spectrometry

LC-HRMS - Liquid Chromatography-High-Resolution Mass Spectrometry

OUR CAPABILITIES



STORAGE

- 5000 pallet storage capacity



REGULATORY AFFAIRS

- Dossier Compilation
- Product Registration
- Lifecycle Management



SALES & DISTRIBUTION

- Public sector
- Private sector



SUSTAINABLE MANUFACTURING





Our Commitment to Sustainable Manufacturing

At Qcil, sustainability is central to our business strategy. As a leading pharmaceutical manufacturer in Sub-Saharan Africa, we are committed to striking a balance between financial success, environmental responsibility, social impact, and strong governance.

Our approach integrates sustainability into every aspect of our operations, from reducing our environmental footprint and expanding access to healthcare to upholding the highest ethical standards.

Guided by the United Nations Sustainable Development Goals (SDGs), especially Goals 3 (Good health and wellbeing), 6 (Clean water and sanitation), 8 (Decent work and economic growth), 9 (Industry, innovation, and infrastructure), 12 (Responsible consumption and production), and 13 (Climate action), we aim to create lasting value for patients, communities, and stakeholders.






Our Commitment to Sustainable Manufacturing

We have developed a framework, **AIR**, to drive sustainable growth while producing high-quality, affordable medicines in Africa for Africa. It aligns with global standards such as the **UN SDGs**, **GRI**, **IFRS S1/S2**, and **SASB**, while reflecting Qcil's unique identity and purpose.

- **Access with Integrity:** Guaranteeing equitable access to essential medicines while upholding the highest ethical standards.
- **Identity with Impact:** Strengthening our brand through social responsibility and community engagement.
- **Resilient and Responsible Operations:** Embedding safe, sustainable practices that protect employees, communities, and the environment.

Just as clean air sustains life, AIR symbolises our commitment to people, planet, and performance, ensuring growth with integrity, purpose, and long-term impact.

We focus on four (4) key drivers for environmental impact



We are ISO standards certified, which reflects our culture of responsibility and excellence.




— Demonstrates our structured approach to minimizing our environmental footprint while ensuring efficient resource use and driving continuous improvement in our sustainability practices.



— Affirms our commitment to providing a safe, and healthy workplace where employee wellbeing comes first, preventing injuries and fostering a safety first culture.

OUR SOCIAL IMPACT

EMPLOYEE GROWTH IN NUMBERS:



PHARMACEUTICAL INDUSTRY CAPACITY BUILDING:



OVER 900 INTERNS AND GRADUATE TRAINEES



have gone through Qcil, both from Ugandan Universities and from other African countries, like pharmacy students from the University of Namibia, that we train annually.



Internship students & staff after completing their training at Qcil.



OUR PORTFOLIO

> Therapeutic Areas



Malaria



HIV AIDS



Diabetes



Hypertension



Fungal Infections



Bacterial Infections



Allergies




Gastrointestinal



Malaria



HIV AIDS



Our product list keeps on evolving, please enquire for latest products through bd@qcil.com
Products should be taken under strict guidance of the healthcare practitioners, pictures are for display only and proprietary to Qcil.

Diabetes



Hypertension



Fungal Infections



Bacterial Infections



Bacterial Infections



Our product list keeps on evolving, please enquire for latest products through bd@qcil.com
Products should be taken under strict guidance of the healthcare practitioners, pictures are for display only and proprietary to Qcil.

Allergies

Methaler

MONTELUKAST PIVATATE NASAL SPRAY (0.05%)/0.05% (50 MICROGRAMS)



E-fet

LEVOCETIRIZINE DIHYDROCHLORIDE TABLETS USP 5 MG



Gastrointestinal

RightM

RABEPRAZOLE TABLETS 20 MG



Reproductive Health

Stenofil

Sildenafil Citrate Tablets USP 50 mg



Over-the-Counter (OTCs)




Our product list keeps on evolving, please enquire for latest products through bd@qcil.com
Products should be taken under strict guidance of the healthcare practitioners, pictures are for display only and proprietary to Qcil.

OUR PRIORITIES



Ensuring Availability and Affordability by manufacturing in Africa

Adding markets, capacity and capability



Ensuring access of new products through an Africa focused portfolio

Product development, in-licensing, technology partnership




Building Private Market segment in the region

Leveraging manufacturing and portfolio strength to address access and availability of quality products in Private Market in the region and beyond





OUR GROWING CAPABILITY & CAPACITY



BLOCK-1
(EXISTING PLANT BUILDING)

BLOCK-4A
(EXISTING UTILITY BLDG.)

BLOCK-4B
(PROPOSED UTILITY BUILDING)

BLOCK-2
(UNDER CONSTRUCTION)

BLOCK-3A
(EXISTING WAREHOUSE)

BLOCK-3B
(CYTOTOXIC FACILITY)

BLOCK-5
(ADMIN AND R & D)

BLOCK-6
(CENTRAL DINING)
(UNDER CONSTRUCTION)

BLOCK-8
(GATE CABIN 1)



Quality Chemical Industries Limited, Plot 1-7, 1st Ring Road, Luzira
Industrial Park, P.O.Box 34871, Kampala, Uganda
Office Tel +256 312 341 100 | Email: contactus@qcil.com

